Products

The major epidemic caused by a novel (new) coronavirus (named “SARS-CoV-2”), which was first discovered in Wuhan, China, at the end of 2019, has once again brought coronavirus to people's attention. Since the SARS epidemic at the end of 2002, Creative Biolabs has conducted extensive and in-depth research on coronaviruses. Especially for SARS-CoV, MERS-CoV with high infection rate, high morbidity and mortality, we have prepared a series of high-quality products for the development of anti-CoV drugs and vaccines. Benefit from the accumulated rich experience, we quickly developed corresponding products immediately after the outbreak of 2019-nCoV, to help fuel the process of developing targeted drugs and vaccines.

For SARS-CoV-2, SARS-CoV, MERS-CoV and other important coronaviruses, we have prepared and launched significant proteins, antibodies, viral receptor molecules, and related plasmid and cell overexpression lysate products.